{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T16:11:23Z","timestamp":1794845483527,"version":"4.9.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:00:00Z","timestamp":1764201600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"vor","delay-in-days":39,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Insulin resistance (IR) is increasingly linked with poor cancer prognosis, but its impact on mortality among breast cancer patients\u2014particularly regarding different causes of death\u2014remains incompletely understood. The estimated glucose disposal rate (eGDR) is a surrogate index of insulin sensitivity. This study intended to investigate the links of eGDR with all-cause mortality (ACM) and breast cancer-specific mortality (BCSM) in US breast cancer survivors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Data were sourced from the 2007\u20132016 National Health and Nutrition Examination Survey(NHANES). A cross-sectional design was used to assess the link between eGDR and breast cancer prevalence, while a cohort design was adopted for mortality follow-up. Additionally, weighted logistic regression was leveraged to estimate the link between eGDR and breast cancer prevalence. Cox models were employed to evaluate the relationship between eGDR and ACM. Restricted cubic splines were utilized to model nonlinear links, and competing risk models were adopted to analyze BCSM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 323 women with breast cancer, 73 deaths occurred during follow-up (median 6.2 years). After multiple confounders were controlled, a binary analysis using optimal cutoff values confirmed that higher eGDR was independently linked with lower ACM risk (HR: 0.40; 95% CI: 0.18\u20130.89;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.025). This association was nonlinear, and the protective effect remained across multiple subgroups. In competing risk analysis, a potential association was observed between higher eGDR and lower BCSM risk (HR: 0.13; 95% CI: 0.02\u20130.99;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.048), with no marked association observed for cardiovascular mortality.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In US breast cancer survivors, higher eGDR was independently linked with lower ACM risk. This association may be partly driven by a reduction in BCSM, but this specific finding requires validation in larger studies due to considerable statistical uncertainty.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-025-15340-0","type":"journal-article","created":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T06:04:19Z","timestamp":1764223459000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Association of estimated glucose disposal rate with all-cause and breast cancer-specific mortality in US breast cancer survivors: a population-based study"],"prefix":"10.1186","volume":"26","author":[{"given":"Jinhao","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiasheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingliang","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuansheng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,27]]},"reference":[{"issue":"9472","key":"15340_CR1","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1016\/S0140-6736(05)66546-4","volume":"365","author":"U Veronesi","year":"2005","unstructured":"Veronesi U, Boyle P, Goldhirsch A, Orecchia R, Viale G. Breast cancer. Lancet. 2005;365(9472):1727\u201341.","journal-title":"Lancet"},{"issue":"3","key":"15340_CR2","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"15340_CR3","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.breast.2022.08.010","volume":"66","author":"M Arnold","year":"2022","unstructured":"Arnold M, Morgan E, Rumgay H, Mafra A, Singh D, Laversanne M, et al. Current and future burden of breast cancer: global statistics for 2020 and 2040. Breast. 2022;66:15\u201323.","journal-title":"Breast"},{"issue":"Suppl 2","key":"15340_CR4","doi-asserted-by":"crossref","first-page":"S135","DOI":"10.1055\/s-2001-18576","volume":"109","author":"HE Lebovitz","year":"2001","unstructured":"Lebovitz HE. Insulin resistance: definition and consequences. Exp Clin Endocrinol Diabetes. 2001;109(Suppl 2):S135\u2013148.","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"5","key":"15340_CR5","first-page":"480","volume":"73","author":"LA Huppert","year":"2023","unstructured":"Huppert LA, Gumusay O, Idossa D, Rugo HS. Systemic therapy for hormone receptor-positive\/human epidermal growth factor receptor 2-negative early stage and metastatic breast cancer. CA Cancer J Clin. 2023;73(5):480\u2013515.","journal-title":"CA Cancer J Clin"},{"issue":"7","key":"15340_CR6","doi-asserted-by":"crossref","first-page":"e303","DOI":"10.1016\/S1470-2045(20)30666-5","volume":"22","author":"MA Franzoi","year":"2021","unstructured":"Franzoi MA, Agostinetto E, Perachino M, Del Mastro L, de Azambuja E, Vaz-Luis I, et al. Evidence-based approaches for the management of side-effects of adjuvant endocrine therapy in patients with breast cancer. Lancet Oncol. 2021;22(7):e303\u201313.","journal-title":"Lancet Oncol"},{"key":"15340_CR7","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s12943-015-0482-2","volume":"15","author":"BC Luey","year":"2016","unstructured":"Luey BC, May FE. Insulin-like growth factors are essential to prevent Anoikis in oestrogen-responsive breast cancer cells: importance of the type I IGF receptor and PI3-kinase\/Akt pathway. Mol Cancer. 2016;15:8.","journal-title":"Mol Cancer"},{"issue":"9","key":"15340_CR8","doi-asserted-by":"crossref","first-page":"11711","DOI":"10.1007\/s13277-016-5176-x","volume":"37","author":"M Motallebnezhad","year":"2016","unstructured":"Motallebnezhad M, Aghebati-Maleki L, Jadidi-Niaragh F, Nickho H, Samadi-Kafil H, Shamsasenjan K, et al. The insulin-like growth factor-I receptor (IGF-IR) in breast cancer: biology and treatment strategies. Tumour Biol. 2016;37(9):11711\u201321.","journal-title":"Tumour Biol"},{"issue":"8","key":"15340_CR9","doi-asserted-by":"crossref","first-page":"665","DOI":"10.2174\/156800961508151001101742","volume":"15","author":"O Menyh\u00e1rt","year":"2015","unstructured":"Menyh\u00e1rt O, Santarpia L, Gy\u0151rffy B. A comprehensive outline of trastuzumab resistance biomarkers in HER2 overexpressing breast cancer. Curr Cancer Drug Targets. 2015;15(8):665\u201383.","journal-title":"Curr Cancer Drug Targets"},{"issue":"3","key":"15340_CR10","first-page":"E214","volume":"237","author":"RA DeFronzo","year":"1979","unstructured":"DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol. 1979;237(3):E214\u2013223.","journal-title":"Am J Physiol"},{"issue":"3","key":"15340_CR11","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/jch.14155","volume":"23","author":"HV Minh","year":"2021","unstructured":"Minh HV, Tien HA, Sinh CT, Thang DC, Chen CH, Tay JC, et al. Assessment of preferred methods to measure insulin resistance in Asian patients with hypertension. J Clin Hypertens (Greenwich). 2021;23(3):529\u201337.","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"3","key":"15340_CR12","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S1521-690X(03)00042-3","volume":"17","author":"G Pacini","year":"2003","unstructured":"Pacini G, Mari A. Methods for clinical assessment of insulin sensitivity and beta-cell function. Best Pract Res Clin Endocrinol Metab. 2003;17(3):305\u201322.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"9","key":"15340_CR13","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.2337\/dc10-0286","volume":"33","author":"JP van Melle","year":"2010","unstructured":"van Melle JP, Bot M, de Jonge P, de Boer RA, van Veldhuisen DJ, Whooley MA. Diabetes, glycemic control, and new-onset heart failure in patients with stable coronary artery disease: data from the heart and soul study. Diabetes Care. 2010;33(9):2084\u20139.","journal-title":"Diabetes Care"},{"issue":"3","key":"15340_CR14","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1111\/dom.13110","volume":"20","author":"T Nystr\u00f6m","year":"2018","unstructured":"Nystr\u00f6m T, Holzmann MJ, Eliasson B, Svensson AM, Sartipy U. Estimated glucose disposal rate predicts mortality in adults with type 1 diabetes. Diabetes Obes Metab. 2018;20(3):556\u201363.","journal-title":"Diabetes Obes Metab"},{"key":"15340_CR15","doi-asserted-by":"crossref","unstructured":"Chiefari E, Mirabelli M, La Vignera S, Tanyola\u00e7 S, Foti DP, Aversa A, et al. Insulin resistance and cancer: in search for a causal link. Int J Mol Sci. 2021;22(20):11137.","DOI":"10.3390\/ijms222011137"},{"issue":"22","key":"15340_CR16","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.1001\/jama.283.22.2975","volume":"283","author":"HG Welch","year":"2000","unstructured":"Welch HG, Schwartz LM, Woloshin S. Are increasing 5-year survival rates evidence of success against cancer? JAMA. 2000;283(22):2975\u20138.","journal-title":"JAMA"},{"key":"15340_CR17","unstructured":"Curtin LR, Mohadjer LK, Dohrmann SM, Kruszon-Moran D, Mirel LB, Carroll MD, et al. National health and nutrition examination survey: sample design, 2007\u20132010. Vital Health Stat 2. 2013;(160):1\u201323."},{"issue":"4","key":"15340_CR18","doi-asserted-by":"crossref","first-page":"626","DOI":"10.2337\/diabetes.49.4.626","volume":"49","author":"KV Williams","year":"2000","unstructured":"Williams KV, Erbey JR, Becker D, Arslanian S, Orchard TJ. Can clinical factors estimate insulin resistance in type 1 diabetes? Diabetes. 2000;49(4):626\u201332.","journal-title":"Diabetes"},{"key":"15340_CR19","doi-asserted-by":"crossref","first-page":"101966","DOI":"10.1016\/j.canep.2021.101966","volume":"73","author":"F Guo","year":"2021","unstructured":"Guo F, Wang M, Guo X, Pu L, Sun M, Li S, et al. The association between fatty acid intake and breast cancer based on the NHANES and Mendelian randomization study. Cancer Epidemiol. 2021;73:101966.","journal-title":"Cancer Epidemiol"},{"key":"15340_CR20","doi-asserted-by":"crossref","first-page":"1053665","DOI":"10.3389\/fendo.2023.1053665","volume":"14","author":"C Liu","year":"2023","unstructured":"Liu C, Zhao M, Zhao Y, Hu Y. Association between serum total testosterone levels and metabolic syndrome among adult women in the united States, NHANES 2011\u20132016. Front Endocrinol (Lausanne). 2023;14:1053665.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"3","key":"15340_CR21","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1053\/j.ajkd.2015.10.018","volume":"67","author":"X Chen","year":"2016","unstructured":"Chen X, Wei G, Jalili T, Metos J, Giri A, Cho ME, et al. The associations of plant protein intake with All-Cause mortality in CKD. Am J Kidney Dis. 2016;67(3):423\u201330.","journal-title":"Am J Kidney Dis"},{"key":"15340_CR22","doi-asserted-by":"crossref","first-page":"1398265","DOI":"10.3389\/fendo.2024.1398265","volume":"15","author":"J Song","year":"2024","unstructured":"Song J, Ma R, Yin L. Associations between estimated glucose disposal rate and arterial stiffness and mortality among US adults with non-alcoholic fatty liver disease. Front Endocrinol (Lausanne). 2024;15:1398265.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"15340_CR23","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s12888-016-0728-6","volume":"16","author":"A Hinz","year":"2016","unstructured":"Hinz A, Mehnert A, Kocalevent RD, Br\u00e4hler E, Forkmann T, Singer S, et al. Assessment of depression severity with the PHQ-9 in cancer patients and in the general population. BMC Psychiatry. 2016;16:22.","journal-title":"BMC Psychiatry"},{"issue":"9","key":"15340_CR24","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1046\/j.1525-1497.2001.016009606.x","volume":"16","author":"K Kroenke","year":"2001","unstructured":"Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16(9):606\u201313.","journal-title":"J Gen Intern Med"},{"key":"15340_CR25","doi-asserted-by":"crossref","unstructured":"Whelton PK, Carey RM, Aronow WS, Casey DE Jr., Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American college of Cardiology\/American heart association task force on clinical practice guidelines. J Am Coll Cardiol. 2018;71(19):e127\u2013e248.","DOI":"10.1016\/j.jacc.2017.11.006"},{"issue":"3","key":"15340_CR26","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1093\/annonc\/mdr160","volume":"23","author":"M Riihim\u00e4ki","year":"2012","unstructured":"Riihim\u00e4ki M, Thomsen H, Brandt A, Sundquist J, Hemminki K. Death causes in breast cancer patients. Ann Oncol. 2012;23(3):604\u201310.","journal-title":"Ann Oncol"},{"issue":"1","key":"15340_CR27","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1186\/s40001-024-01834-3","volume":"29","author":"R Ma","year":"2024","unstructured":"Ma R, Song J, Ding Y. Associations between life\u2019s essential 8 and post-stroke depression and all-cause mortality among US adults. Eur J Med Res. 2024;29(1):229.","journal-title":"Eur J Med Res"},{"issue":"1","key":"15340_CR28","first-page":"10","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. CA Cancer J Clin. 2025;75(1):10\u201345.","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"15340_CR29","doi-asserted-by":"crossref","first-page":"998","DOI":"10.3390\/curroncol31020075","volume":"31","author":"L Szablewski","year":"2024","unstructured":"Szablewski L. Insulin resistance: the increased risk of cancers. Curr Oncol. 2024;31(2):998\u20131027.","journal-title":"Curr Oncol"},{"issue":"16","key":"15340_CR30","doi-asserted-by":"crossref","first-page":"3638","DOI":"10.1002\/cncr.33002","volume":"126","author":"K Pan","year":"2020","unstructured":"Pan K, Chlebowski RT, Mortimer JE, Gunter MJ, Rohan T, Vitolins MZ, et al. Insulin resistance and breast cancer incidence and mortality in postmenopausal women in the women\u2019s health initiative. Cancer. 2020;126(16):3638\u201347.","journal-title":"Cancer"},{"issue":"3","key":"15340_CR31","doi-asserted-by":"crossref","first-page":"285","DOI":"10.4093\/dmj.2020.0250","volume":"45","author":"AMY Zhang","year":"2021","unstructured":"Zhang AMY, Wellberg EA, Kopp JL, Johnson JD. Hyperinsulinemia in Obesity, Inflammation, and cancer. Diabetes Metab J. 2021;45(3):285\u2013311.","journal-title":"Diabetes Metab J"},{"issue":"3","key":"15340_CR32","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1152\/physrev.00030.2014","volume":"95","author":"EJ Gallagher","year":"2015","unstructured":"Gallagher EJ, LeRoith D. Obesity and diabetes: the increased risk of cancer and cancer-Related mortality. Physiol Rev. 2015;95(3):727\u201348.","journal-title":"Physiol Rev"},{"issue":"18","key":"15340_CR33","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1002\/cncr.35318","volume":"130","author":"RT Chlebowski","year":"2024","unstructured":"Chlebowski RT, Aragaki AK, Pan K, Simon MS, Neuhouser ML, Haque R, et al. Breast cancer incidence and mortality by metabolic syndrome and obesity: the women\u2019s health initiative. Cancer. 2024;130(18):3147\u201356.","journal-title":"Cancer"},{"issue":"12","key":"15340_CR34","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/nrneph.2016.145","volume":"12","author":"F Artunc","year":"2016","unstructured":"Artunc F, Schleicher E, Weigert C, Fritsche A, Stefan N, H\u00e4ring HU. The impact of insulin resistance on the kidney and vasculature. Nat Rev Nephrol. 2016;12(12):721\u201337.","journal-title":"Nat Rev Nephrol"},{"issue":"5930","key":"15340_CR35","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1126\/science.1160809","volume":"324","author":"MG Vander Heiden","year":"2009","unstructured":"Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324(5930):1029\u201333.","journal-title":"Science"},{"issue":"4","key":"15340_CR36","first-page":"207","volume":"60","author":"E Giovannucci","year":"2010","unstructured":"Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, et al. Diabetes and cancer: a consensus report. CA Cancer J Clin. 2010;60(4):207\u201321.","journal-title":"CA Cancer J Clin"},{"issue":"11","key":"15340_CR37","first-page":"1361","volume":"11","author":"P Muti","year":"2002","unstructured":"Muti P, Quattrin T, Grant BJ, Krogh V, Micheli A, Sch\u00fcnemann HJ, et al. Fasting glucose is a risk factor for breast cancer: a prospective study. Cancer Epidemiol Biomarkers Prev. 2002;11(11):1361\u20138.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"4","key":"15340_CR38","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1677\/ERC-09-0087","volume":"16","author":"P Vigneri","year":"2009","unstructured":"Vigneri P, Frasca F, Sciacca L, Pandini G, Vigneri R. Diabetes and cancer. Endocr Relat Cancer. 2009;16(4):1103\u201323.","journal-title":"Endocr Relat Cancer"},{"issue":"6","key":"15340_CR39","first-page":"761","volume":"20","author":"V Hwa","year":"1999","unstructured":"Hwa V, Oh Y, Rosenfeld RG. The insulin-like growth factor-binding protein (IGFBP) superfamily. Endocr Rev. 1999;20(6):761\u201387.","journal-title":"Endocr Rev"},{"issue":"2","key":"15340_CR40","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/nrm1837","volume":"7","author":"CM Taniguchi","year":"2006","unstructured":"Taniguchi CM, Emanuelli B, Kahn CR. Critical nodes in signalling pathways: insights into insulin action. Nat Rev Mol Cell Biol. 2006;7(2):85\u201396.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"4","key":"15340_CR41","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/bies.200800210","volume":"31","author":"CW Ward","year":"2009","unstructured":"Ward CW, Lawrence MC. Ligand-induced activation of the insulin receptor: a multi-step process involving structural changes in both the ligand and the receptor. BioEssays. 2009;31(4):422\u201334.","journal-title":"BioEssays"},{"issue":"6","key":"15340_CR42","doi-asserted-by":"crossref","first-page":"R225","DOI":"10.1530\/ERC-12-0203","volume":"19","author":"DP Rose","year":"2012","unstructured":"Rose DP, Vona-Davis L. The cellular and molecular mechanisms by which insulin influences breast cancer risk and progression. Endocr Relat Cancer. 2012;19(6):R225\u2013241.","journal-title":"Endocr Relat Cancer"},{"key":"15340_CR43","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s12943-015-0291-7","volume":"14","author":"PF Christopoulos","year":"2015","unstructured":"Christopoulos PF, Msaouel P, Koutsilieris M. The role of the insulin-like growth factor-1 system in breast cancer. Mol Cancer. 2015;14:43.","journal-title":"Mol Cancer"},{"issue":"2","key":"15340_CR44","doi-asserted-by":"crossref","first-page":"E234","DOI":"10.1152\/ajpendo.00274.2003","volume":"286","author":"R Krogh-Madsen","year":"2004","unstructured":"Krogh-Madsen R, Plomgaard P, Keller P, Keller C, Pedersen BK. Insulin stimulates interleukin-6 and tumor necrosis factor-alpha gene expression in human subcutaneous adipose tissue. Am J Physiol Endocrinol Metab. 2004;286(2):E234\u2013238.","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"6","key":"15340_CR45","doi-asserted-by":"crossref","first-page":"E1276","DOI":"10.1152\/ajpendo.00535.2001","volume":"282","author":"M Soop","year":"2002","unstructured":"Soop M, Duxbury H, Agwunobi AO, Gibson JM, Hopkins SJ, Childs C, et al. Euglycemic hyperinsulinemia augments the cytokine and endocrine responses to endotoxin in humans. Am J Physiol Endocrinol Metab. 2002;282(6):E1276\u20131285.","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"1","key":"15340_CR46","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/s00125-005-0075-5","volume":"49","author":"J Westerbacka","year":"2006","unstructured":"Westerbacka J, Corn\u00e9r A, Kannisto K, Kolak M, Makkonen J, Korsheninnikova E, et al. Acute in vivo effects of insulin on gene expression in adipose tissue in insulin-resistant and insulin-sensitive subjects. Diabetologia. 2006;49(1):132\u201340.","journal-title":"Diabetologia"},{"issue":"5","key":"15340_CR47","doi-asserted-by":"crossref","first-page":"E841","DOI":"10.1152\/ajpendo.00653.2006","volume":"294","author":"J Westerbacka","year":"2008","unstructured":"Westerbacka J, Corn\u00e9r A, Kolak M, Makkonen J, Turpeinen U, Hamsten A, et al. Insulin regulation of MCP-1 in human adipose tissue of obese and lean women. Am J Physiol Endocrinol Metab. 2008;294(5):E841\u2013845.","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"2","key":"15340_CR48","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1007\/s12020-024-03924-y","volume":"86","author":"E Carrillo-Lopez","year":"2024","unstructured":"Carrillo-Lopez E, Sebastian-Valles F, Sager La Ganga C, Ballesteros A, Navas-Moreno V, Ba\u00f1\u00f3n D, et al. Arranz Mart\u00edn JA: C-Peptide and BMi predict anti-hyperglycemic treatment lines in breast cancer patients treated with Alpelisib. Endocrine. 2024;86(2):470\u20137.","journal-title":"Endocrine"},{"issue":"7","key":"15340_CR49","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s12094-009-0384-0","volume":"11","author":"A V\u00e1zquez-Mart\u00edn","year":"2009","unstructured":"V\u00e1zquez-Mart\u00edn A, Oliveras-Ferraros C, del Barco S, Mart\u00edn-Castillo B, Men\u00e9ndez JA. mTOR inhibitors and the anti-diabetic Biguanide metformin: new insights into the molecular management of breast cancer resistance to the HER2 tyrosine kinase inhibitor lapatinib (Tykerb). Clin Transl Oncol. 2009;11(7):455\u20139.","journal-title":"Clin Transl Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15340-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-15340-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15340-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T13:58:38Z","timestamp":1781618318000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-025-15340-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,27]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["15340"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-15340-0","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,27]]},"assertion":[{"value":"10 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study followed the Declaration of Helsinki and was ratified by the NCHS Ethics Committee. Participants offered written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Ethics approval and consent to participate."}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"16"}}